Similar articles

Abstract: fufang Xueshuantong (FXT) is a well-known Chinese herbal formula which has been used to treat cardiovascular and ophthalmic diseases, especially diabetic retinopathy. Panax notoginseng (Burkill) F.H. Chen (PN) is the main herb of FXT, whose major bioactive constituents are ginsenosides. However, the scientific basis of the compatibility of FXT is still ambiguous. The present study investigated the scientific basis of the compatibility of FXT by comparing the pharmacokinetics of marker compounds after oral administrations of PN and FXT. A high performance liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) method was developed for simultaneous detection of notoginsenoside R1 (NR1), ginsenoside Rg1 (GRg1), and ginsenoside Rb1 (GRb1) in rat plasma. The pharmacokinetic studies of FXT and PN were performed using the established method with the pharmacokinetic parameters being determined by non-compartmental analysis. The results showed that the pharmacokinetic parameters (maximum concentration, area under the curve (AUC_0–t), clearance, and mean residence time) of NR1, GRg1, and GRb1 were significantly different after oral administration of FXT (P<0.05) compared with PN. The AUC_0–t values of GRg1 and GRb1 were 1.7- and 3.4-fold greater, respectively, in FXT than in PN. The compatible herbs of FXT could prolong the retention time and increase the systemic exposure of NR1, GRg1, and GRb1 compared with PN in vivo, providing some scientific basis for the compatibility and clinical use of FXT.

复方血栓通中多药配伍对君药三七有效成分药代动力学的影响

[1]Deng, G., Wang, D., Meng, M., et al., 2009. Simultaneous determination of notoginsenoside R1, ginsenoside Rg1, Re, Rb1 and icariin in rat plasma by ultra-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B, 877(22):2113-2122.

[2]Duan, H., Huang, J., Li, W., et al., 2013. Protective effects of Fufang Xueshuantong on diabetic retinopathy in rats. Evid.-Based. Compl. Alt., 2013:408268.

[3]Han, M., Fu, S., Fang, X.L., 2007. Comparison between the characteristics of absorption and pharmacokinetic behavior of ginsenoside Rg1 and ginsenoside Rb1 of Panax notoginseng saponins. Acta Pharmaceut. Sin., 42(8):849-853 (in Chinese).

[4]Hao, H., Lai, L., Zheng, C., et al., 2010. Microsomal cytochrome P450-mediated metabolism of protopanaxatriol ginsenosides: metabolite profile, reaction phenotyping, and structure-metabolism relationship. Drug Metab. Dispos., 38(10): 1731-1739.

[5]Huang, H., Yang, Y., Lv, C., et al., 2015. Pharmacokinetics and tissue distribution of five bufadienolides from the Shexiang Baoxin pill following oral administration to mice. J. Ethnopharmacol., 161:175-185.

[6]Jian, W., Yu, S., Tang, M., et al., 2015. A combination of the main constituents of Fufang Xueshuantong Capsules shows protective effects against streptozotocin-induced retinal lesions in rats. J. Ethnopharmacol., 182:50-56.

[7]Lai, X., Zhang, L., Li, J., et al., 2011. Comparative pharmacokinetic and bioavailability studies of three salvianolic acids after the administration of Salviae miltiorrhizae alone or with synthetical borneol in rats. Fitoterapia, 82(6):883-888.

[8]Lau, C., Mooiman, K.D., Maas-Bakker, R.F., et al., 2013. Effect of Chinese herbs on CYP3A4 activity and expression in vitro. J. Ethnopharmacol., 149(2):543-549.

[9]Lennernas, H., Regardh, C., 1993. Evidence for an interaction between the β-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile. Pharmaceut. Res., 10:819-883.

[10]Liu, R., Qin, M., Hang, P., et al., 2012. Effects of Panax notoginseng Saponins on the activities of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 in rats in vivo. Phytother. Res., 26(8):1113-1118.

[11]Long, W., Zhang, S., Wen, L., et al., 2014. In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration. J. Ethnopharmacol., 156:199-208.

[12]National Pharmacopoeia Committee, 2015. Chinese Pharmacopoeia (2015 Chinese version) Part 1. China Medical Science Press, Beijing, p.1223-1224 (in Chinese).

[13]Ng, T.B., 2006. Pharmacological activity of sanchi ginseng (Panax notoginseng). J. Pharm. Pharmacol., 58(8):1007-1019.

[14]Oberle, R.L., Amidon, G.L., 1987. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J. Pharmacokinet. Biop., 15(5):529-544.

[15]Pedersen, P.V., Miller, R., 1980. Pharmacokinetics and bioavailability of cimetidine in humans. J. Pharm. Sci., 69(4): 394-398.

[16]Sheng, S., Wang, J., Wang, L., et al., 2014. Network pharmacology analyses of the antithrombotic pharmacological mechanism of Fufang Xueshuantong Capsule with experimental support using disseminated intravascular coagulation rats. J. Ethnopharmacol., 154(3):735-744.

[17]Song, M., Hang, T.J., Zhang, Z.X., 2007. Pharmacokinetic interactions between the main components in the extracts of Salvia miltiorrhiza Bge. in rat. Acta Pharm. Sin., 42(3):301-307 (in Chinese).

[18]Wang, Q., Jiang, P., Ye, F., et al., 2014. Identification and pharmacokinetics of multiple constituents in rat plasma after oral administration of Yinchenzhufu decoction. J. Ethnopharmacol., 153(3):714-724.

[19]Wang, X., Yeung, J.H.K., 2010. Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats. J. Pharm. Pharmacol., 62(8):1077-1083.

[20]Wang, X., Yeung, J.H., 2012. Investigation of cytochrome P450 1A2 and 3A inhibitory properties of Danshen tincture. Phytomedicine, 19(3-4):348-354.

[21]Wu, K., Wang, Z., Liu, D., et al., 2014. Pharmacokinetics, brain distribution, release and blood-brain barrier transport of Shunaoxin pills. J. Ethnopharmacol., 151(3):1133-1140.

[22]Xu, Q.F., Fang, X.L., Chen, D.F., 2003. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J. Ethnopharmacol., 84(2-3):187-192.

[23]Yang, S., Zhang, K., Lin, X., et al., 2012. Pharmacokinetic comparisons of single herb extract of Fufang Danshen preparation with different combinations of its constituent herbs in rats. J. Pharmaceut. Biomed., 67-68:77-85.

[24]Yuan, Y., Yuan, F., Xu, Q., et al., 2011. Effect of Fufang Xueshuantong Capsule on a rat model of retinal vein occlusion. Chin. J. Integr. Med., 17(4):296-301.

[25]Zhang, Q., Xiao, X., Li, M., et al., 2013. Attenuating effect of Fufang Xueshuantong Capsule on kidney function in diabetic nephropathy model. J. Nat. Med., 67(1):86-97.